verrica logo.jpg
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum
December 15, 2021 16:05 ET | Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
verrica logo.jpg
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
November 29, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
verrica logo.jpg
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
November 18, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST...
verrica logo.jpg
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 12, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA...
verrica logo.jpg
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
September 20, 2021 16:05 ET | Verrica Pharmaceuticals Inc.
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer No Clinical, Safety or CMC Issues Specific to...
verrica logo.jpg
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 10, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
verrica logo.jpg
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
July 09, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....
verrica logo.jpg
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
May 28, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 – WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”)...
verrica logo.jpg
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference
May 26, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
verrica logo.jpg
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 07:30 ET | Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...